Chronic Myeloproliferative Disorders Completed Phase 2 Trials for Tanespimycin (DB05134)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT0013201517-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic MastocytosisTreatment